Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns: -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (3266)	4/3/2014 10:40:40 AM
From: The Ox	Respond to of 8288

Jeffries out defending CLDX but you'd never know by the action today, falling knife!! Celldex Therapeutics Inc. (NASDAQ: CLDX) has several pipeline immunotherapies, including rindopepimut, a Phase 3 immunotherapy that stimulates responses against specific types of brain tumor cells. One of the most exciting areas of drug development currently is the immuno-oncology space. Potential cancer cures and the multibillion dollar sales potential that coincide with these cures have raised company valuations and acquisition interest to obtain drugs in this category. This is another one of Jefferies’ top drug innovations for 2014. Celldex is Buy-rated at Jefferies, and the price target is $31. The consensus target is a whopping $36.33. Celldex closed Wednesday at $17.79.

To: The Ox who wrote (3266)	4/11/2014 2:44:56 PM
From: The Ox	Read Replies (1) \| Respond to of 8288

CLDX alert went off at $14.10, fwiw. Falling knife, so even though it's hit our buy level, we may wait to see some sort of support first. Down from $32 about 6 weeks ago.